News

Icagen and Pfizer have jointly presented the data related to their collaboration focused on certain sodium channels for the treatment of pain and related conditions at the Neuroscience

LDN Research Trust has said that the lives of 100,000 multiple sclerosis (MS) sufferers in the UK could be greatly improved while saving the National Health Service (NHS)

According to the findings of European Sexual Confidence Survey, 87% of adults believe that good sex is linked to a man’s ability to achieve and sustain a firm

Velocity Medical Solutions (VMS) has launched a new subscription service designed to provide adaptive radiation therapy to hospitals and radiation oncology centers with minimal up-front capital investment. Reportedly,

Biogen Idec and Biovitrum are planning to advance their long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients. Reportedly, the

Rexahn Pharmaceuticals (Rexahn) has reported top-line results from a phase IIa clinical study of Serdaxin, its major depressive disorder (MDD) drug candidate. Reportedly, the randomised, double blind, placebo

The FDA has approved GlaxoSmithKline’s (GSK) Votrient (pazopanib) to treat patients with advanced renal cell carcinoma (RCC). Votrient, a once-daily, oral medication, is an angiogenesis inhibitor which may

XenoPort has initiated a phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD), who remain symptomatic despite treatment

Talecris Biotherapeutics (Talecris) has received approval from the FDA for Prolastin-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of Prolastin produced using advances in manufacturing technology. Like Prolastin,